Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Modeling Luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in Luminal disease.

Knox AJ, Scaling AL, Pinto MP, Bliesner BS, Haughian JM, Abdel-Hafiz HA, Horwitz KB.

Breast Cancer Res. 2014 Aug 13;16(4):418. [Epub ahead of print]

PMID:
25116921
[PubMed - as supplied by publisher]
2.

Post-translational modifications of the progesterone receptors.

Abdel-Hafiz HA, Horwitz KB.

J Steroid Biochem Mol Biol. 2014 Mar;140:80-9. doi: 10.1016/j.jsbmb.2013.12.008. Epub 2013 Dec 12. Review.

PMID:
24333793
[PubMed - indexed for MEDLINE]
3.

Control of progesterone receptor transcriptional synergy by SUMOylation and deSUMOylation.

Abdel-Hafiz HA, Horwitz KB.

BMC Mol Biol. 2012 Mar 22;13:10. doi: 10.1186/1471-2199-13-10.

PMID:
22439847
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Structural determinants outside of the leucine zipper influence the interactions of CREB and ATF-2: interaction of CREB with ATF-2 blocks E1a-ATF-2 complex formation.

Abdel-Hafiz HA, Chen CY, Marcell T, Kroll DJ, Hoeffler JP.

Oncogene. 1993 May;8(5):1161-74.

PMID:
8479741
[PubMed - indexed for MEDLINE]
5.

Activating transcription factor-2 DNA-binding activity is stimulated by phosphorylation catalyzed by p42 and p54 microtubule-associated protein kinases.

Abdel-Hafiz HA, Heasley LE, Kyriakis JM, Avruch J, Kroll DJ, Johnson GL, Hoeffler JP.

Mol Endocrinol. 1992 Dec;6(12):2079-89.

PMID:
1337144
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk